MedWatch

Ambu to reign in expectations after seventh downgrade since 2019

Juan Jose Gonzalez has been the chief executive of Ambu since 2019, and since then, the medtech firm has downgraded its guidance seven times. Going forward, expectations will fall on the conservative side, he says.

Juan Jose Gonzales, CEO of Ambu | Photo: Ambu/PR

After seven downgrades, four falling consecutively in the most recent financial reports, CEO of Ambu Juan Jose Gonzalez will start being more conservative when making future predictions, he says in an interview with MedWatch.

On Thursday, Ambu downgraded its guidance for the 2021/2022 financial year, now expecting a minimum organic growth of 13% compared to a previous minimum of 15%, and an EBIT (earnings before interest and taxes) margin of at least 5% instead of at least 7%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs